

*Cont*

wherein R<sup>1</sup> represents amino, hydroxy or acylamino having 2 to 30 carbon atoms; R<sup>2</sup> represents hydrogen, halogen, a lower alkyl, a lower alkenyl, a lower alkynyl or haloalkyl; R<sup>3</sup> and R<sup>4</sup> may be the same or different and represent hydrogen, stearoyl or aminoacyl, or a pharmaceutically acceptable salt or hydrate thereof, except that when R<sup>1</sup> is amino or hydroxy, and both of R<sup>3</sup> and R<sup>4</sup> may not be hydrogen.

b - Claim 2, cancel without prejudice to the subject matter

thereof, and add the following claim in its place:

--12. A compound or a pharmaceutically acceptable salt or hydrate thereof as claims in claim 11 which is selected from the group consisting of 2'-deoxy-2'-methylidene-5'-0-stearoylcytidine and 5'-0-(2-amino-3-methylvarleryl)-2'-deoxy-2'-methylidenecytidine.

#### REMARKS

The claims are 11 and 12.

The above amendment deletes all amendments to the specification made in the parent application. Therefore, the original specification is restored to exactly correspond to the issued patent.

However, since the specification contained several typographical errors, these have been corrected by a Request for Certificate of Correction, a copy of which is enclosed. The original Request has been filed in the original patent with the Certificate of Corrections Branch.

Further, claims 3 to 8 of the parent application have been deleted and previous claims 1 and 2 of the parent application have been rewritten as new claims 11 and 12, respectively.

The only difference between new claims 11 and 12 and claims 1 and 2 of the original patent is that the definition of R<sup>1</sup> has been broadened in claim 11 to include the case where R<sup>1</sup> represents acylamino having 2 to 30 carbon atoms.